Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study

Table 2 The treatment and management of ECMO

	Survivors ( n = 13)	Non-survivors ( n = 9)	P value
Steroid therapy	7 (54%)	2 (22%)	0.15
IABP use	13 (100%)	8 (89%)	0.41
CHDF use	2 (15%)	3 (33%)	0.32
Total operating time of ECMO, h	181 ± 22	177 ± 31	0.15
Complications associated with ECMO
Total	3 (23%)	8 (89%)	0.004
Leg ischemia	0 (0%)	2 (22%)	0.16
Stroke	0 (0%)	2 (22%)	0.16
Bleeding	2 (15%)	6 (67%)	0.02
Multiple organ failure	2 (15%)	6 (67%)	0.02

Data are presented as the mean ± standard deviation or as the number of patients (%).
IABP intra-aortic balloon pump, CHDF continuous hemodiafiltration.